Sharing cost analysis by username Bridge to sell f
Post# of 153776
(Total Views: 577)
Posted On: 01/08/2021 10:35:00 AM
Sharing cost analysis by username Bridge to sell from YMB:
Ok, so the big news today is the accelerated 10-Q filing. Logic would dictate that this was a major prerequisite to NASDAQ uplisting if that is going to happen. That doesn't mean that uplisting will occur, but I suspect that without the 10-Q it definitely could not have.
Also of interest if you read the 10-Q is some detail about pricing. On page 36 we see that the company claims current inventory on hand is $29.7 million (drug product) and $41.1 million (bulk drug). The CEO has recently stated during the conference call Q&A that there are 500,000 doses available with the ability to produce another 700,000 doses right away.
These numbers correlate remarkably. If we have 500,000 doses that cost the company $29.7 million, then the average cost (to CYDY) per dose is approximately $59.40. The CEO has previously stated that they intend to charge $1,200 per dose, which means that Vyrolgix at retail has a cost of 5% and profit margin of 95% (excluding marketing, distribution, etc.).
To back this up we also have the value of the unbottled inventory in the 10-Q which is stated to be $41.1 millon. Again, Nader was kind enough to tell us that we also have access to another 700,000 doses that are un-bottled. Simple arithmetic indicates that the unbottled cost per dose is approximately $58.71. This makes sense if you allow for the difference of $0.69 per vial for the bottling process that Samsung would have to charge to turn bulk product into usable doses.
So for anyone wanting to get a better understanding of potential profitability, we now have excellent data on what Vyrologix actually costs versus what it is intended to be sold for. Even at a deeply discounted rate to countries like the Philippines or Brazil, there is tremendous profit in selling this drug.
I would add one additional thought though. These are current costs and do not take into account any money previously spent in developing and accrediting the manufacturing process, which need to be amortized over time into the per/dose cost structure.
Good luck fellow longs.
Ok, so the big news today is the accelerated 10-Q filing. Logic would dictate that this was a major prerequisite to NASDAQ uplisting if that is going to happen. That doesn't mean that uplisting will occur, but I suspect that without the 10-Q it definitely could not have.
Also of interest if you read the 10-Q is some detail about pricing. On page 36 we see that the company claims current inventory on hand is $29.7 million (drug product) and $41.1 million (bulk drug). The CEO has recently stated during the conference call Q&A that there are 500,000 doses available with the ability to produce another 700,000 doses right away.
These numbers correlate remarkably. If we have 500,000 doses that cost the company $29.7 million, then the average cost (to CYDY) per dose is approximately $59.40. The CEO has previously stated that they intend to charge $1,200 per dose, which means that Vyrolgix at retail has a cost of 5% and profit margin of 95% (excluding marketing, distribution, etc.).
To back this up we also have the value of the unbottled inventory in the 10-Q which is stated to be $41.1 millon. Again, Nader was kind enough to tell us that we also have access to another 700,000 doses that are un-bottled. Simple arithmetic indicates that the unbottled cost per dose is approximately $58.71. This makes sense if you allow for the difference of $0.69 per vial for the bottling process that Samsung would have to charge to turn bulk product into usable doses.
So for anyone wanting to get a better understanding of potential profitability, we now have excellent data on what Vyrologix actually costs versus what it is intended to be sold for. Even at a deeply discounted rate to countries like the Philippines or Brazil, there is tremendous profit in selling this drug.
I would add one additional thought though. These are current costs and do not take into account any money previously spent in developing and accrediting the manufacturing process, which need to be amortized over time into the per/dose cost structure.
Good luck fellow longs.
(13)
(0)